ISRCTN55212198 https://doi.org/10.1186/ISRCTN55212198

Reimbursement for smoking cessation treatment

Submission date	Recruitment status	[ ] Prospectively registered
12/09/2005	No longer recruiting	[ ] Protocol
Registration date	**Overall study status**	[ ] Statistical analysis plan
12/09/2005	Completed	[X] Results
Last Edited	**Condition category**	[ ] Individual participant data
10/09/2009	Mental and Behavioural Disorders	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr J. Kaper

Contact details
Care and Public Health Research Institute (CAPHRI), Maastricht University
P.O. Box 616
Maastricht
Netherlands
6200 MD
+31 (0)43 3882420
janneke.kaper@hag.unimaas.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
NTR104; STIVORO and the Dutch Asthma Foundation 3.4.03.28

Study information

Scientific Title
(Added 18/08/09) The (cost)-effectiveness of reimbursement for smoking cessation treatment

Study objectives
Reimbursement for smoking cessation treatment will increase the use of the treatment and the number of quit attempts. The increased use of smoking cessation treatment by reimbursement will result into increased prolonged abstinence.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Approved by the Medical Ethics Committee of the Trimbos Institute in Utrecht, The Netherlands (May 2005).

Study design
Random consent design

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Other

Study type(s)
Other

Participant information sheet

Health condition(s) or problem(s) studied
Smoking cessation

Interventions
For a period of 6 months, smokers in the intervention group had the opportunity to apply for reimbursement for SCT. They received a leaflet with a description of the SCTs for which reimbursement was available, and information on how to receive the reimbursement. Smokers in the intervention group could receive full reimbursement for pharmacological treatment (bupropion and NRT (chewing gum, patch, tablet, sublingual tablet and inhaler)), behavioural counselling (written advice, telephone or face to face counselling) or a combination. To receive reimbursement, they had to send the receipt and two statements of personal contact with a health care professional (general practitioner, general practice nurse, physician, psychologist or health community worker) to the health insurance company. Before the study started, all the health care professionals in the study region were informed about the study. No limit was set on the number of applications for reimbursement. In the control, no reimbursement or information about smoking cessation treatment was offered.

Intervention Type
Other

Phase
Not Specified

Primary outcome measure
The primary outcome measure of the reimbursement study was continuous abstinence from smoking. Continuous abstinence was defined as not having smoked for at least seven days preceding the 6-month and 12-month questionnaire and not having relapsed between both questionnaires. After the 6-month and 12-month questionnaire, quitters were contacted to make an appointment for biochemical validation of their smoking status.

Secondary outcome measures
Secondary outcomes were the use of smoking cessation treatment, the number of quit attempts that were undertaken, and the cost-effectiveness of reimbursement was assessed.

Overall study start date
01/05/2002

Completion date
01/05/2003

Eligibility

Key inclusion criteria
We included smokers of at least 18 years old and healthcare insured by health insurance company "De Friesland Zorgverzekeraar". Participants did not have to be motivated to quit smoking.

Participant type(s)
Patient

Age group
Adult

Lower age limit
18 Years

Sex
Both

Target number of participants
1,266

Key exclusion criteria
Only one smoker per household was allowed to participate.

Date of first enrolment
01/05/2002

Date of final enrolment
01/05/2003

Locations

Countries of recruitment
Netherlands

Study participating centre
Care and Public Health Research Institute (CAPHRI), Maastricht University
Maastricht
Netherlands
6200 MD

Sponsor information

Organisation
CAPHRI research institute, University Maastricht (Netherlands)

Sponsor details
P.O box 616
Maastricht
Netherlands
6200 MD

Sponsor type
University/education

Website
http://www.caphri.nl/

ROR
https://ror.org/02jz4aj89

Funder(s)

Funder type
Charity

Funder Name
Dutch Asthma Foundation (Netherlands)

Funder Name
STIVORO (Netherlands)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/07/2005		Yes	No
Results article	results on cost effectiveness	01/07/2006		Yes	No
Results article	results on sustained abstinence	01/11/2006		Yes	No